Since leaving Pfizer to go back to academia in 2007, Andrew Hopkins (University of Dundee, UK) has been a leading researcher in the search for new informatics and computational methods to improve the design of effective drug candidates against G-protein coupled receptors and other prominent drug classes. In this presentation, Hopkins reviews his groups latest progress using Bayesian approaches for Algorithmic Drug Design, which show immense promise for the identification of new classes of small molecule drug compounds.
Research And Development
Medical Laboratory Technician50%
Manufacturer - Other50%